ISGCT 2025 Posters Exhibition
ISGCT 2025 Posters Exhibition
- - Developing Off-the-Shelf T-cell Receptor Therapy Targeting Resistant Pathogens Using CRISPR Genome-Editing (Exhibition Hall)
- - The human natural killer (NK) cell line YTS as a novel platform for cellular therapy (Exhibition Hall)
- - Targeted Therapeutic Release via Ultrasound Nanodroplets for Tumor Therapy (Exhibition Hall)
- - Engager-mediated targeting of lentiviral vectors to specific cell types (Exhibition Hall)
- - Manufacturing outcomes for cGMP-grade gamma retroviral vectors for ex-vivo manufacturing of effector T cell therapies (Exhibition Hall)
- - Qualification of a qPCR-based Mycoplasma assay under cGMP for release of effector T cell products (Exhibition Hall)
- - A novel T cell receptor targeting mutated KRAS identified in the peripheral blood of a pancreatic cancer patient (Exhibition Hall)
- - In Vivo Site-Specific T Cell Engineering Allows Complete Remission of Human Leukemia in Mice (Exhibition Hall)
- - T-Boost: Enhancing the Potency, Persistence, and Tumor Resistance of T and NK Cell Therapies for Hematologic and Solid Tumors (Exhibition Hall)
- - Streamlining CAR T Cell Manufacturing: Automated CD19 CAR-T Production Using the Cocoon® Platform in a Phase 2 Clinical Trial (Exhibition Hall)
- - AI-Designed Immune Sensor-Enhanced CAR-T Cells for Potent Solid Tumor Immunotherapy (Exhibition Hall)
- - T cell engineering using V(D)J recombination allows tumor growth inhibition in mice (Exhibition Hall)
- - Neuron-Specific AAV-Mediated WWOX Gene Therapy Rescues Mortality and
Seizure Phenotypes in WOREE Syndrome Models (Exhibition Hall)
- - High-Coverage Whole-Genome Sequencing Uncovers Complex CRISPR-Induced Genomic Rearrangements in Human Hematopoietic Stem Cells (Exhibition Hall)
- - Genome Editing Using Lipid Nanoparticles for Mantle Cell Lymphoma Therapy (Exhibition Hall)
- - Discovery and Functional Characterization of Cytotoxic Cells in Planarians (Exhibition Hall)
- - Candidate stem cell isolation and transplantation in Hexacorallia (Exhibition Hall)
- - Computational design of optimized and preferentially paired human TCR constant regions for improved T-cell function (Exhibition Hall)
- - P6-SN38: A Novel EGFR-Targeting Cyclic Peptide–Drug Conjugate with Potent Activity Against NSCLC" (Exhibition Hall)
- - Precise Correction of Patient-Derived HSPCs Enables T Cell Differentiation in a Personalized SCID Gene Editing Strategy (Exhibition Hall)
- - Targeting Mutated p53 for Cancer Therapeutics using Lipid Nanoparticles (Exhibition Hall)
- - Dual CAR Strategy for Specific and Safe Targeting of T-Cells Against Ovarian
Cancer (Exhibition Hall)
- - Synthetic mammalian RNA-based gene circuits for high-fold changes in expression (Exhibition Hall)
- - In Vivo AAV Delivery of Anti-CD19 CAR in Murine and Humanized SLE Models (Exhibition Hall)
- - The majority of genetic point mutations can be reinstated by DNA and RNA base editors (Exhibition Hall)
- - Using Lipid Nanoparticles to Deliver Genetic Medicine for Duchenne Muscular Dystrophy (Exhibition Hall)
- - Adult Stem / Progenitor Cells as a Personalized Treatment for Vascular Diseases (Main Hall,Exhibition Hall)
- - The potential use of CAR EV’s as a therapeutic strategy for lung cancer (Exhibition Hall)
- - Personalized Lung Cancer Treatment Using Antisense Oligonucleotides (Exhibition Hall)
- - Highly Efficacious Allogeneic CAR-MAIT Cells Targeting Solid Tumors (Main Hall,Exhibition Hall)
- - CRISPR/Cas9 Genome Editing Using Lipid Nanoparticles for Hepatocellular Carcinoma Therapy (Main Hall,Exhibition Hall)
- - CAR T-Cells Are Dysfunctional In The CNS (Main Hall,Exhibition Hall)
- - Successful Phase 1/2a Trial for Treating Chronic Hard to Heal Diabetic Foot Ulcers (Main Hall,Exhibition Hall)
- - Precise Correction of Patient-Derived HSPCs Enables T Cell Differentiation in a Personalized SCID Gene Editing Strategy (Main Hall,Exhibition Hall)
